Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies

A method for prolonging survival of a cancer patient, wherein the cancer is associated with cells expressing IL1RAP the method comprising administering to the cancer patient (a) a therapeutically effective amount of an antibody that has binding specificity for human interleukin-1 receptor accessory protein (IL1RAP), and (b) one or more further therapeutic agents, thereby increasing the cancer patient's likelihood of survival as compared to a control patient who receives treatment comprising the one or more further therapeutic agents but not the antibody that has binding specificity for human interleukin-1 receptor accessory protein (IL1RAP), wherein the one or more further therapeutic agents are chemotherapeutic and/or immunotherapeutic agents, and wherein the antibody comprises:

• a. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFTSS (amino acids 26-32 of SEQ ID NO:
• 9);
• (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO:
• 4);
• and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
• 5);
• and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO:
• 16);
• (ii) light chain CDR2 comprising YTSGLHA (SEQ ID NO:
• 13);
• and (iii) light chain CDR3 comprising:
• QQYSILPWT (SEQ ID NO:
• 14);
• b. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFTSS (amino acids 26-32 of SEQ ID NO:
• 9);
• (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO:
• 4);
• and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
• 5);
• and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO:
• 12);
• light chain CDR2 comprising YTSGLHA (SEQ ID NO:
• 13);
• and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
• 14);
• c. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFSSS (SEQ ID NO:
• 3);
• (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO:
• 4);
• and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
• 5);
• and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO:
• 12);
• light chain CDR2 comprising YTSGLHA (SEQ ID NO:
• 13);
• and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
• 14);
• d. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFSSS (SEQ ID NO:
• 3);
• (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO:
• 4);
• and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
• 5);
• and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO:
• 16);
• light chain CDR2 comprising YTSGLHA (SEQ ID NO:
• 13);
• and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
• 14);
• e. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYTFTSS (amino acids 26-32 of SEQ ID NO:
• 10);
• (ii) heavy chain CDR2 comprising YPGDGQ (amino acids 52-57 of SEQ ID NO:
• 10);
• and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
• 5);
• and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO:
• 12);
• light chain CDR2 comprising YTSGLHA (SEQ ID NO:
• 13);
• and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
• 14);
• or
• f. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYTFTSS (amino acids 26-32 of SEQ ID NO:
• 10);
• (ii) heavy chain CDR2 comprising YPGDGQ (amino acids 52-57 of SEQ ID NO:
• 10);
• and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
• 5);
• and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO:
• 16);
• light chain CDR2 comprising YTSGLHA (SEQ ID NO:
• 13);
• and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
• 14).